NCT07730905Completed
Analysis of Renal Impairment Characteristics and High-Risk Factors in Chronic Hepatitis B Patients on Long-Term Oral Nucleos(t)Ide Analogues
Analysis of Renal Impairment Characteristics and High-Risk Factors in Patients With Chronic Hepatitis B Receiving Long-Term Oral Nucleos(t)Ide Analogues
Source: ClinicalTrials.gov · Last updated 28 Jul 2026
Brief summary (registry, in English)
This is a single-center retrospective observational study. A total of 300 patients with non-alcoholic fatty liver disease treated in our hospital will be included. We collect clinical data, laboratory indicators and imaging results, and analyze the correlation between long-term nucleoside antiviral drugs and renal function changes in patients. The study does not use any new intervention measures, and only conducts statistical analysis on existing medical record data.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 300 (actual)
- First submitted
- 1 Jul 2026
- Start date
- 4 Sept 2024
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Foshan Hospital of Traditional Chinese Medicine
- NCT number
- NCT07730905
What you commit to
- Study type: Observational
- Participants enrolled: 300
- From 4 Sept 2024 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Combined with chronic nephritis, nephrotic syndrome and other primary kidney diseases.
- Co-infection with hepatitis C virus, hepatitis E virus and other hepatitis viruses.
- Patients with drug resistance during anti-HBV treatment who switched or combined other antiviral agents.
- Autoimmune hepatitis, alcoholic liver disease, schistosomal liver disease and other liver diseases.
- Malignant tumor, severe cardiovascular and other systemic serious diseases.
Other
- Duration of antiviral treatment less than 12 months.
Who the study is looking for
- Meet the diagnostic criteria for chronic hepatitis B specified in the 2019 Chinese Society of Infectious Diseases guidelines.
- Patients received continuous NAS antiviral treatment for at least 12 months.
- Patients voluntarily participated in the study and signed informed consent.
- Complete records of liver function, renal function, urinary indicators and HBV-DNA data are available.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Foshan Hospital of Traditional Chinese Medicine Coordinator of this site? Confirm its status | Foshan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.